Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This clinical trial is for men and women age ≥ 18 years old who have been diagnosed with advanced rectum cancer.

Key Inclusion / Exclusion Criteria:

   • Open to men and women, Age ≥18 years at the time of informed consent who have been diagnosed with invasive primary rectal cancer
   • No prior pelvic radiotherapy, chemotherapy, immunotherapy or other anti-cancer treatment for rectal cancer
   • Ability to read and provide signed informed consent. Patients may not be consented by a durable power of attorney.
   • Ability and willingness to comply with scheduled study visits, treatment plans, laboratory tests and other study related procedures 

Additional eligibility criteria reviewed when you contact the study team. 

This clinical trial is for men with high risk, localized prostate cancer. The most common treatment options for men with clinically localized prostate cancer include radical prostatectomy (surgical removal of the prostate) and radiation therapy (uses radiation to kill cancer cells).

Key Inclusion / Exclusion Criteria:
  • Men age 18 and older. 
  • Diagnosis of prostate cancer 
  • No prior treatment for prostate cancer. 
  • Detailed eligibility reviewed when you contact the study team. 

This clinical trial is to evaluate an experimental (investigational) drug in men or women with Nonalcoholic Steatohepatitis (NASH) and liver fibrosis.

Key Inclusion / Exclusion Criteria:

- Men and women who are 18 years of age and older. 
- Treatment naïve individuals with Nonalcoholic Steatohepatitis (NASH) and liver fibrosis. 
- Detailed eligibility reviewed when you contact the study team. 

This clinical trial is for men and women with metastatic colorectal cancer (CRC). Following progression on first-line FOLFOX or XELOX with bevacizumab, patients will be randomized in a 1:1 ratio to BBI-608 plus biweekly FOLFIRI or biweekly FOLFIRI.

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older 
  • Histologically confirmed advanced CRC that is metastatic. 
  • Must have failed treatment with one regimen containing a fluoropyrimidine, oxaliplatin and bevacizumab for metastatic disease. All patients must have received a minimum of 6 weeks of the first-line regimen that included bevacizumab, oxaliplatin and a fluoropyrimidine in the same cycle. Treatment failure is defined as radiologic progression during or < 6 months after the last dose of first-line therapy. 
  • Detailed eligibility reviewed when you contact the study team. 

Video of A Phase III Study of BBI-608 and FOLFIRI in Patients with Metastatic Colorectal Cancer

This behavioral intervention trial is intended for women newly diagnosed with gestational diabetes mellitus (GDM).

Key Inclusion / Exclusion Criteria:
  • Women 18 years of age or older
  • Newly diagnosed with gestational diabetes mellitus between 24-28 weeks of gestation
  • Detailed eligibility reviewed when you contact the study team 

The purpose of this study is to create an extensive database in the cardiac electrophysiology laboratory. The researchers will conduct a post-study survey to determine the cardiac status of all patients who undergo an electrophysiology procedure.

Key Inclusion / Exclusion Criteria:
  • Male or female between the ages of 18 and 100
  • Inpatient or outpatient scheduled for an electrophysiology procedure
  • Able to sign consent and agree to be contacted via telephone for 10 years post-procedure
  • More detailed information ise available from study staff.

CREST-2 is a study for people who have narrowing of their carotid artery without symptoms caused by that artery like small strokes or temporary strokes. Temporary strokes are often called transient ischemic attacks or TIAs.

Key Inclusion / Exclusion Criteria:

Men and women who:

  • Are 35 years and older 
  • Have narrowing (70% or greater) of at least one of their carotid arteries
  • Lack other serious medical complications

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.